The National Institutes of Health might just have the best news for patients with relapsing-remitting multiple sclerosis, a condition that the central nervous system is attacked by the immune system. The trial carried out for the high-dose immunosuppressive therapy, and autologous hematopoietic cell transplant has shown a sixty-five percent improvement; the patients who did not even take MS medication after the procedure did not experience any disabilities or even relapse of the symptoms. The director of National Institute of Allergy and Infectious Diseases, Anthony Fauci, said the trial revealed that one-time HDIT/HCT treatment is more effective than long-term MS drugs in the market.
The testing which was for five years was done to twenty-four volunteers with relapsing-remitting MS, the volunteers had taken available medication for the illness but still had symptoms which range from fatigue, speech and motor disability to chronic pain and weakness and other patients had experienced brain disability. The treatment entails drawing the stem cells from the body then the patient undergoes chemotherapy to finish the immune system and then the stem cells are returned to rebuild the immune system. After the treatment, most patients remained in remission and their health improved. Dr. Richard Nash who was the principal at the investigation said despite the fact more tests need to be done there is high hope for the treatment. HDIT/HCT could be the best therapeutic option for MS patients.
Dr. Shiva Gopal Vasishta is a neurologist and psychiatrist at Eastern Neurodiagnostic Associates and Kennedy University Hospital. Dr. Shiva Gopal Vasishta is involved in Medicare program, and he is licensed to work in New Jersey.
Dr. Shiva Gopal Vasishta went to Government Medical College Nagpur where he received his medical degree, and he did his residency at Boston City Hospital. Sivan Gopal Vasishta has over thirty years of experience in neurology, and he is a very sought after doctor.